Effect of Superba Krill on Inflammation in Patients With Coronary Artery Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01092793|
Recruitment Status : Unknown
Verified March 2010 by Oslo University Hospital.
Recruitment status was: Recruiting
First Posted : March 25, 2010
Last Update Posted : March 25, 2010
Atherosclerotic coronary heart disease is a condition thought to involve low-grade inflammation. Several reports, clinical and epidemiological, have demonstrated that intake of fish oil may be beneficial in attenuating the inflammatory process. Still, however, there are lacking data in respect to whether differences in composition of various marine oils may influence the inflammatory status differently.
The hypothesis of the current study is that extract from the antarctic krill (Euphausia superba) is better than traditional fish oils when compared head-to-head with balanced composition of omega 3 content on inflammatory status.
|Condition or disease||Intervention/treatment|
|Stable Atherosclerotic Coronary Disease||Dietary Supplement: Krill Dietary Supplement: Fish oil|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Masking:||None (Open Label)|
|Official Title:||Effect of Superba Krill on Inflammation in Patients With Coronary Artery Disease|
|Study Start Date :||February 2010|
|Estimated Primary Completion Date :||January 2011|
|Estimated Study Completion Date :||January 2011|
|Active Comparator: Krill||Dietary Supplement: Krill|
|Active Comparator: Fish oil||Dietary Supplement: Fish oil|
|No Intervention: Control|
- Inflammatory blood status [ Time Frame: 8 weeks intervention ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01092793
|Contact: Lars Gullestad, Professor, MD, PhD||+47 23070641||Lars.Gullestad@rikshospitalet.no|
|Contact: Leif Erik Vinge, MD, PhD||+47 email@example.com|
|Department of Cardiology, Oslo University Hospital / Rikshospitalet||Recruiting|
|Oslo, Norway, 0027|
|Contact: Lars Gullestad, Professor, MD, PhD +47 23070641 Lars.Gullestad@rikshospitalet.no|
|Contact: Leif Erik Vinge, MD, PhD +47 95970301 firstname.lastname@example.org|